LINCOLN, Neb. (KOLN) -After nearly 30 years of pediatric brain cancer research only one new drug treatment has been approved by the U.S Food and Drug Administration, that’s according to pediatric researchers at the University of Nebraska Medicine.
Dr. Sidharth Mahapatra, a member of UNMC’s Pediatric Cancer Research Group, said the treatment works but attacks the body indiscriminately.
“We’re still using a hammer approach to try and kill cancer cells, and what that does is it kills the cancer, but it causes a tremendous amount of damage,” Dr. Mahapatra said…